Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma

[1]  Yong Yi,et al.  Recent updates on Sintilimab in solid tumor immunotherapy , 2020, Biomarker research.

[2]  T. Liang,et al.  Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression , 2020, Frontiers in Immunology.

[3]  L. Shen,et al.  Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial , 2020, BMC Cancer.

[4]  Ying Cheng,et al.  Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11). , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Q. Gao,et al.  2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. , 2020, Hepatobiliary surgery and nutrition.

[6]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[7]  W. Huang,et al.  Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients , 2020, Annals of translational medicine.

[8]  Biao Zhu,et al.  Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma , 2020, Annals of translational medicine.

[9]  W. Fang,et al.  Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. , 2020, The Lancet. Oncology.

[10]  M. Kudo,et al.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Lei Zhang,et al.  Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma , 2019, Cancer management and research.

[12]  M. Kudo,et al.  CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) , 2019, Annals of Oncology.

[13]  M. Kudo,et al.  Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis. , 2019, Journal of hepatology.

[14]  Tongyu Lin,et al.  A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma , 2019, Clinical Cancer Research.

[15]  C. Porta,et al.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.

[16]  J. Trojan,et al.  Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort , 2019, Alimentary pharmacology & therapeutics.

[17]  Bing-he Xu,et al.  Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210 , 2019, Cancer biology & medicine.

[18]  Sheridan M. Hoy.  Sintilimab: First Global Approval , 2019, Drugs.

[19]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[20]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2019, Clinical Liver Disease.

[21]  Wei Li,et al.  Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. , 2019, The Lancet. Haematology.

[22]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[23]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[24]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[25]  M. Kudo,et al.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.

[26]  Ning Wang,et al.  Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. , 2018, The Lancet. Global health.

[27]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[28]  Cancer in Australia: Actual incidence data from 1982 to 2013 and mortality data from 1982 to 2014 with projections to 2017 , 2018, Asia-Pacific journal of clinical oncology.

[29]  P. Hegde,et al.  Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. , 2017, Seminars in cancer biology.

[30]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[31]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[32]  G. Keating.  Sorafenib: A Review in Hepatocellular Carcinoma , 2017, Targeted Oncology.

[33]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[34]  Suzanne F. Jones,et al.  Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.

[35]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[36]  M. Plummer,et al.  World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma , 2015, Hepatology.

[37]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[38]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.